

# Review of Serology Tests for Lyme Disease

Susan Best  
National Serology Reference Laboratory  
Melbourne, Australia  
[www.nrl.gov.au](http://www.nrl.gov.au)

Gary Lum AM  
Specialist Medical Advisor  
Office of Health Protection  
Department of Health  
Canberra, Australia



# Presentation outline

- Australian situation re LD and *Borrelia*
- Australian Govt interest in Lyme Disease (LD)
- Role in this conference
- Project

# National Serology Reference Laboratory, Australia (NRL)

- Established in 1985
- Service provider to Australian Government
  - Evaluate test kits
  - Provide quality assurance programmes
    - HIV; other blood borne viruses (BBV)
- WHO Collaborating Centre
- Regional reference testing centre for BBV

# NRL Credentials

- Accredited:
  - Medical testing laboratory (ISO 15189)
  - Provider of quality assurance (ISO 17043)
- Licensed to code of Good Manufacturing Practice
- Certified:
  - ISO 9001:2000 (Management standard)
  - AS/NZS 4801:2001 (OHS standard)

# Lyme Disease: Australian Situation

- Lyme borreliosis reports in Australia
  - Majority in travelers to endemic areas
  - Some reports in non-travelers
    - Positive results could not be repeated in recognised algorithms

# Australian Situation – Ticks (1)

- *B. burgdorferi* transmitted by *Ixodes* ticks.  
However:
  - No *I. ricinus* members in Aust
  - *I. holocyclus* is abundant on NSW N coast
    - One report of *Borrelia* spp
    - Cultures were unconfirmed and unsustainable
    - This tick unable to be infected by *B. burgdorferi*
- *Amblyomma* present in WA
  - Spp not associated with *Borrelia*

# Australian Situation – Ticks (2)

- Russell RC *et al* 1994, 1995
  - 11,000 ticks examined: 12 spp
    - Microscopy, culture
    - No spirochaetes detected
  - 1,000 ticks examined
    - PCR
    - No *Borrelia spp*
- Mayne PJ 2012
  - Reported *B. burgdorferi* detected by PCR in Australian patients with EM
  - Further work needed for verification

# Australian Situation – Laboratories and Testing

- Few laboratories test for *Borrelia*
  - Fewer perform confirmatory testing
- Generally, 2-tier algorithm used
  - Immunoassay; immunoblot
- Generally commercial tests used
  - In-house WB used up until recently
  - In-house PCR



# Australian Situation – Laboratories and Testing

- Some specimens sent to US / Germany for confirmatory testing
  - ± Different results
  - Casts doubt on results from Australian labs
  - Quandary for Govt
- Increased focus
  - Validation of tests and modifications
  - Quality assurance measures

# Project background

- Aust Govt established a Clinical Advisory Committee on LD

## 1. *Does indigenously acquired LD exist in Aust?*

- Two schools of thought:

- Indigenous form of LD exists
- Indigenous form may exist but proof necessary
  - Definition of causative organism and its vector

## 2. *Testing for LD*

- Algorithms including confirmatory testing, PCR, laboratory accreditation

## 3. *Treatment*

# Project background

- Aust Govt needs clarification of local LD situation
- Multi-faceted approach necessary
- Sought assistance from NRL for review of testing
  - NRL is independent
  - Strengths:
    - serology and molecular testing
    - assay validation, algorithm validation, QA
    - operates within highly developed Quality Mgt System
  - Coordinate a collaborative project

# ***Borrelia* testing in humans**

- Complex, evolving picture
  - Different *Borrelia spp* cause different disease
  - *Borrelia spp* are geographically contained
    - Different manifestations in different countries
  - “Chronic LD”: non-specific symptoms, no case definition
  - Discovery of new *Borrelia* species

# ***Borrelia* testing in humans**

- Serology assays prepared with native and/or recombinant and/or peptide Ags
  - → Assays with different sensitivity and specificity
  - → Discordant results when used in combination
- Low sensitivity in early disease → false neg results
- High false positive rates

***CONFUSION !!***


# ***Borrelia* testing in humans**

- In serology, IgM assays notoriously prone to false positive results
- In early stage LD, IgM tests may be useful
- BUT need to interpret results cautiously
- Significant false positive results in syndromes from which LD might be differentiated

# ***Borrelia* testing in humans**

- Two-tier algorithm significantly increases specificity
  - Criteria for interpreting immunoblot variable
  - CDC criteria may not be appropriate in non-US specimens

# Types of Tests - Serology



positive control  
Weak reaction  
negative control





# ***Borrelia* testing in humans**

- Serology mainstay of laboratory testing
- Direct detection currently unreliable
  - Extremely few spirochaetes present in infected tissues
    - Culture: protracted, insensitive
    - PCR : inconsistently positive

# Project Objectives

- To generate a complete set of test results
  - in the range of IgG serology assays used by Project collaborators
  - on specimens collected from individuals both with and without symptoms of Lyme Disease
  - European, US and Australian specimens
- To use the set of test results to elucidate the relative performance of these assays

# The Project: Collaborators

- Four laboratories in Australia
- Four laboratories outside Australia
  - UK; Germany; USA
- Information on test kits used
- Agreement to provide specimens

# The Project: Specimens

- European / US specimens previously tested for LD
  - Positive, negative, inconclusive
- Australian specimens previously tested for LD
  - Positive (limited numbers), negative, inconclusive
- Australian blood donors
  - Not tested for LD
  - Low risk for LD

# The Project: Specimens

	Europe	USA	Australia
Positive	≥110	20	≥50
Negative (with LD like symptoms)	≥120	20	200
Inconclusive	≥55	20	20
Negative blood donors (no symptoms)	-	-	300-400

- Appropriately stored ( $\leq -20^{\circ}\text{C}$ ) and transported
- Adequate volume for testing in multiple assays
- LD testing history known
- Numbers: balance between efficacy and cost

# The Project: Assays

- All IgG tests used by all collaborators
  - Only IgG in the first instance
    - Avoid IgM false positive
    - Australian cases assumed not early
    - Discordant specimens further evaluated
  - Immunoassays and immunoblots
  - Commercial and in-house
  - Test kit manufacturers' instructions will be followed

# The Project: Assays

## Immunoassays

- Siemens Enzygnost VIsE (native, rec)
- Immunitics C6 (peptide)
- Trinity Biotech MarDx *B. burgdorferi* (native)
- NovaTec NovaLisa *B. burgdorferi* (rec)
- Euroimmun anti-*Borrelia* Select (rec)

## Immunoblots

- Viramed *Borrelia* ViraStripe (mainly rec)
- Mikrogen *recomLine* *Borrelia* (rec)
- IgeneX Lyme western blot (native)
- Euroimmun anti-*Borrelia* – Euroline – RN – AT (native and rec)

# The Project: Testing

## ● Two phases:

● Phase 1: Positive specimens from LD prevalent countries

Blood donors from Australia

Assembled into blinded panel



Good estimates of PPV and NPV

● Phase 2: Positive specimens from Australia  
Negative specimens from individuals with symptoms

Inconclusive specimens

## ● Testing in one lab only



● Reduce variability; maximise specimen volume



# Positive and negative predictive values

## Positive Predictive Value:

The likelihood of a sample identified as positive by an assay being truly POSITIVE for the analyte in question.

## Negative Predictive Value:

The likelihood that a sample identified as a negative by an assay is truly NEGATIVE for the analyte in question.

# The Project: Testing

## ● Two phases:

● Phase 1: Positive specimens from LD prevalent countries

Blood donors from Australia

Assembled into blinded panel



Good estimates of PPV and NPV

● Phase 2: Positive specimens from Australia  
Negative specimens from individuals with symptoms


Inconclusive specimens

## ● Testing in one lab only



● Reduce variability; maximise specimen volume

# The Project: Phase 1 Algorithm




# The Project: Analysis

- With specimen numbers proposed:
  - $\approx 90\%$  confidence of detecting moderate differences between the assays
- To detect smaller differences or with greater confidence:
  - Positive and negative specimen numbers exceed 1,000 each

# The Project: Analysis

- Starting with results in disparate combinations of assays
- Ending with results across the combinations of assays
- Ideal outcome:
  - Tests with good performance identified
  - Tests that perform well together identified
  - Testing in Aust labs shown to be high quality



*Thank you  
for your attention!*